The company's market cap is $3.21 billion. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company's stock valued at $371,846,000 after purchasing an additional 895,584 shares in the last quarter.
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The stock increased 1.28% or $0.84 on September 15, reaching $66.43. About 863,491 shares traded or 99.81% up from the average. Agios Pharmaceuticals Inc (AGIO) has risen 8.52% since September 17, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.
Daruma Capital Management Llc decreased Digitalglobe Inc (DGI) stake by 6.41% reported in 2016Q4 SEC filing. Weybosset Research & Management Llc sold 219,151 shares as the company's stock declined 14.59% while stock markets rallied. Guggenheim holds 50,272 shares. It has underperformed by 40.98% the S&P500. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Therefore 13% are positive. The rating was initiated by Needham with "Buy" on Monday, October 24. As per Friday, October 28, the company rating was downgraded by Wunderlich. The stock of DigitalGlobe Inc (NYSE:DGI) has "Market Perform" rating given on Friday, October 30 by Raymond James. The firm has "Neutral" rating given on Monday, November 9 by Roth Capital. Credit Suisse has "Outperform" rating and $70 target. Pnc Ser Inc invested in 0% or 155 shares.
On Thursday, July 20th, Lewis Clayton Jr. LAUTMAN MARTIN R had bought 507 shares worth $4,943.
Investors sentiment decreased to 0.99 in Q4 2016. Its down 0.50, from 1.13 in 2016Q3. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 1,780 shares. 36 funds opened positions while 52 raised stakes. Moreover, Tfs Capital Llc has 0.42% invested in the company for 144,575 shares. First Manhattan stated it has 1,250 shares. Bnp Paribas Arbitrage has 11,240 shares for 0% of their portfolio. Fred Alger Management holds 0% of its portfolio in DigitalGlobe Inc (NYSE:DGI) for 26,869 shares. Gsa Cap Ptnrs Llp accumulated 0.01% or 21,923 shares. 64,480 are held by Salient Cap Advsrs Limited Co. Lord Abbett Ltd reported 161,836 shares. The New York-based Citigroup Inc has invested 0% in StoneMor Partners L.P. (NYSE:STON). 780 were reported by Cordasco. Arrowstreet Capital Partnership invested in 0.02% or 225,640 shares. 10,301 were reported by Weybosset And Mgmt Limited Liability.
Since March 20, 2017, it had 0 buys, and 7 sales for $906,379 activity. Cantley Lewis Clayton Jr. sold $95,885 worth of stock or 2,036 shares. Cantley sold 3,500 shares of Agios Pharmaceuticals stock.
Traders are a little more bullish on shares of Agios Pharmaceuticals, Inc. recently if you consider the fall in short interest. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since September 16, 2016 and is uptrending. Its up 0.04, from 0.78 in 2016Q3. It worsened, as 38 investors sold Huntington Bancshares Incorporated shares while 179 reduced holdings. 19 funds opened positions while 56 raised stakes.
Shares of Agios Pharmaceuticals, Inc. After $0.03 actual EPS reported by DigitalGlobe Inc for the previous quarter, Wall Street now forecasts -266.67% negative EPS growth.
Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $67.74.
The following firms have recently changed their position in AGIO. Massachusetts-based Fmr Ltd Liability Com has invested 0.04% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Capital International Ltd Ca, a California-based fund reported 344,137 shares. Great West Life Assurance Can accumulated 3,002 shares. Columbia Wanger Asset Mgmt Ltd Limited Liability Company owns 636,290 shares. State Common Retirement Fund owns 68,720 shares. The shares were sold at an average price of $56.14, for a total transaction of $196,490.00. Cap Guardian Trust has invested 0.27% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded up 1.28% during mid-day trading on Thursday, reaching $66.43. Finally, BidaskClub upgraded shares of Agios Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, July 13th. Therefore 50% are positive. The legal version of this piece can be read at https://www.truebluetribune.com/2017/09/15/agios-pharmaceuticals-inc-agio-receives-new-coverage-from-analysts-at-royal-bank-of-canada.html. As per Tuesday, August 8, the company rating was maintained by Oppenheimer. Leerink Swann downgraded the stock to "Market Perform" rating in Monday, December 7 report. The firm has "Neutral" rating by TH Capital given on Monday, November 9. The firm earned "Equal-Weight" rating on Tuesday, May 17 by Morgan Stanley. SunTrust Banks, Inc. restated a buy rating and set a $80.00 target price (up previously from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday, August 8th. The company was maintained on Tuesday, June 6 by Cowen & Co. If you are accessing this news story on another publication, it was illegally copied and republished in violation of global copyright & trademark law. Oppenheimer maintained it with "Buy" rating and $7500 target in Sunday, June 11 report.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.